Nanoparticle Delivery Gap in Immune Cell Engineering: Endosomal Escape May Be the Key Bottleneck
Published in Immunology, Journals, Nanomedicine.
A new review in the International Journal of Nanomedicine argues that one of the main limitations in nanoparticle-based immune-cell engineering may not be getting nanoparticles into cells, but getting their therapeutic cargo out of endosomes and into the cytosol.
This process, known as endosomal escape, can determine whether nucleic acids, proteins or other therapeutic payloads reach the intracellular machinery they are intended to modify.
A design challenge for nano-engineered cell therapies
The authors review nanoparticle uptake, intracellular trafficking, immune activation and different strategies for improving endosomal escape. They also discuss manufacturing, safety and regulatory considerations that will affect translation into therapies such as engineered immune cells.
The review proposes that standardized measures of endosomal escape and more reproducible manufacturing could be high-impact priorities for advancing nanoparticle-enabled immune-cell therapies.
Source: International Journal of Nanomedicine — The Nanoparticle Delivery Gap in Immune Cell Engineering.